Newsfeeds Archive - Spark Newswire

2 minute read

Rhythm Pharmaceuticals Presents Data From Phase 3 Pediatrics Trial At Pediatric Endocrine Society Annual Meeting

May 6, 8:15 AM

-- Oral presentation showcased previously disclosed data that demonstrate setmelanotide achieved 3.04 mean reduction in BMI-Z score and 18.4 percent mean reduction in BMI in 12 patients ages 2-<6yo with obesity due to

RYTM

3 minute read

Rhythm Pharmaceuticals Announces Publication Of Results From Phase 2 Study Of Setmelanotide For The Treatment Of Hypothalamic Obesity In The Lancet Diabetes & Endocrinology

By Benzinga Newsdesk

April 29, 6:49 PM

- Publication highlights administration of setmelanotide therapy resulted in a mean percent reduction in BMI of 15% at 16 weeks and 26% at one year of treatment - - Topline data from ongoing pivotal Phase 3 clinical

RYTM

3 minute read

Analyst Ratings

Analyst Expectations For Rhythm Pharmaceuticals’s Future

By Benzinga Insights

April 26, 9:01 AM

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Rhythm Pharmaceuticals…

RYTM

2 minute read

Uncategorized

Jim Cramer Is ‘Willing To Let This Pharma Stock Catch Fire,’ Advises Not To Sell McKesson

By Avi Kapoor

April 19, 8:46 AM

The "Mad Money" host recommended buying some Marvell Technology, and then wait until under $60 to buy the rest.

ASPN

4 minute read

Analyst Ratings

5 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know

By Benzinga Insights

April 10, 12:00 PM

Analysts’ ratings for Rhythm Pharmaceuticals (NASDAQ:RYTM) over the last quarter vary from bullish to bearish, as provided by…

RYTM

1 minute read

Rhythm Pharmaceuticals Announces Approval Reimbursement Decision In Italy For IMCIVREE For The Treatment Of Obesity And Control Of Hunger In Bardet-Biedl Syndrome

By Benzinga Newsdesk

February 7, 9:25 AM

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced

RYTM

3 minute read

Analyst Ratings

Rhythm Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)

By Benzinga Insights

January 25, 1:00 PM

7 analysts have expressed a variety of opinions on Rhythm Pharmaceuticals (NASDAQ:RYTM) over the past quarter, offering a…

RYTM

4 minute read

Analyst Ratings

The Analyst Verdict: Rhythm Pharmaceuticals In The Eyes Of 7 Experts

By Benzinga Insights

January 4, 12:00 PM

Rhythm Pharmaceuticals (NASDAQ:RYTM) has been analyzed by 7 analysts in the last three months, revealing a diverse range…

RYTM

2 minute read

Analyst Ratings

Analyst Expectations for Rhythm Pharmaceuticals’s Future

By Benzinga Insights

December 7, 11:00 AM

Within the last quarter, Rhythm Pharmaceuticals (NASDAQ:RYTM) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

RYTM

1 minute read

Rare Genetic Diseases Of Obesity-Focused Rhythm Pharma’s Bardet-Biedl Syndrome Drug Meets Primary Goal In Pediatric Trial

By Vandana Singh

December 6, 2:36 PM

During the R&D event for investors, Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) released new topline data from its Phase 3 pediatrics trial evaluating one year of setmelanotide in patients aged two and below six years with Bardet-Biedl syndrome (BBS) or proopiomelanocortin (POMC) or leptin recep

RYTM